Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue Medication
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophageal Squamous Cell Carcinoma
Conditions
Esophageal Squamous Cell Carcinoma
Trial Timeline
Jul 30, 2025 → Jan 4, 2032
NCT ID
NCT06780111About Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue Medication
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue Medication is a phase 1/2 stage product being developed by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06780111. Target conditions include Esophageal Squamous Cell Carcinoma.
What happened to similar drugs?
19 of 20 similar drugs in Esophageal Squamous Cell Carcinoma were approved
Approved (19) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06780111 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Esophageal Squamous Cell Carcinoma